![InnerPageHeaderImg_BGinitiative_3](http://drjosephgathe.com/wpsite/wp-content/uploads/2021/06/InnerPageHeaderImg_BGinitiative_3.png)
CJS-US-380 1490 (HIV)
The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.
For more information on this clinical trail Click Here.